Literature DB >> 3864485

Antitumour imidazotetrazines--XI: Effect of 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one [CCRG 81045; M and B 39831 NSC 362856] on poly(ADP-ribose) metabolism.

M J Tisdale.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3864485      PMCID： PMC1977218          DOI： 10.1038/bjc.1985.259

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  17 in total

1.  The involvement of poly(ADP-ribose) polymerase in the degradation of NAD caused by gamma-radiation and N-methyl-N-nitrosourea.

Authors:  C J Skidmore; M I Davies; P M Goodwin; H Halldorsson; P J Lewis; S Shall; A A Zia'ee
Journal:  Eur J Biochem       Date:  1979-11-01

2.  Stimulation of poly(ADP-ribose) polymerase activity by the anti-tumour antibiotic, streptozotocin.

Authors:  W J Whish; M I Davies; S Shall
Journal:  Biochem Biophys Res Commun       Date:  1975-07-22       Impact factor: 3.575

3.  Poly (ADP-ribose) polymerase activity in nucleotide permeable cells.

Authors:  H Halldorsson; D A Gray; S Shall
Journal:  FEBS Lett       Date:  1978-01-15       Impact factor: 4.124

4.  Involvement of poly (ADP-ribose) metabolism in induction of differentiation of HL-60 promyelocytic leukemia cells.

Authors:  M Kanai; M Miwa; T Kondo; Y Tanaka; M Nakayasu; T Sugimura
Journal:  Biochem Biophys Res Commun       Date:  1982-03-30       Impact factor: 3.575

5.  Inducers of erythroid differentiation in K562 human leukemia cells.

Authors:  P T Rowley; B M Ohlsson-Wilhelm; B A Farley; S LaBella
Journal:  Exp Hematol       Date:  1981-01       Impact factor: 3.084

6.  Relation of poly(adenosine diphosphoribose) synthesis to DNA synthesis and cell growth.

Authors:  N A Berger; G Weber; A S Kaichi; S J Petzold
Journal:  Biochim Biophys Acta       Date:  1978-06-22

7.  DNA cross-linking and cytotoxicity in normal and transformed human cells treated in vitro with 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d] -1,2,3,5-tetrazin-4(3H)-one.

Authors:  N W Gibson; J A Hickman; L C Erickson
Journal:  Cancer Res       Date:  1984-05       Impact factor: 12.701

8.  Antitumour imidazotetrazines--IV. An investigation into the mechanism of antitumour activity of a novel and potent antitumour agent, mitozolomide (CCRG 81010, M & B 39565; NSC 353451).

Authors:  C M Horgan; M J Tisdale
Journal:  Biochem Pharmacol       Date:  1984-07-15       Impact factor: 5.858

9.  Measurements of DNA damage in Chinese hamster cells treated with equitoxic and equimutagenic doses of nitrosoureas.

Authors:  L C Erickson; M O Bradley; K W Kohn
Journal:  Cancer Res       Date:  1978-10       Impact factor: 12.701

10.  Induction of haemoglobin synthesis in the human leukaemia cell line K562 by monomethyltriazenes and imidazotetrazinones.

Authors:  M J Tisdale
Journal:  Biochem Pharmacol       Date:  1985-06-15       Impact factor: 5.858
View more
  6 in total

Review 1.  Marine Mollusk-Derived Agents with Antiproliferative Activity as Promising Anticancer Agents to Overcome Chemotherapy Resistance.

Authors:  Maria Letizia Ciavatta; Florence Lefranc; Marianna Carbone; Ernesto Mollo; Margherita Gavagnin; Tania Betancourt; Ramesh Dasari; Alexander Kornienko; Robert Kiss
Journal:  Med Res Rev       Date:  2016-12-07       Impact factor: 12.944

2.  A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy.

Authors:  Stephanie Ströbele; Matthias Schneider; Lukas Schneele; Markus D Siegelin; Lisa Nonnenmacher; Shaoxia Zhou; Georg Karpel-Massler; Georg Karpel-Massle; Mike-Andrew Westhoff; Marc-Eric Halatsch; Klaus-Michael Debatin
Journal:  PLoS One       Date:  2015-06-29       Impact factor: 3.240

3.  Cytotoxicity of 5-(3-methyl-1-triazeno)imidazole-4-carboxamide (MTIC) on Mer+, Mer+Rem- and Mer- cell lines: differential potentiation by 3-acetamidobenzamide.

Authors:  J M Lunn; A L Harris
Journal:  Br J Cancer       Date:  1988-01       Impact factor: 7.640

4.  3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity.

Authors:  S R Wedge; J K Porteous; E S Newlands
Journal:  Br J Cancer       Date:  1996-10       Impact factor: 7.640

5.  Inhibition of the PI3K but not the MEK/ERK pathway sensitizes human glioma cells to alkylating drugs.

Authors:  Bodo Haas; Veronika Klinger; Christina Keksel; Verena Bonigut; Daniela Kiefer; Julia Caspers; Julia Walther; Maria Wos-Maganga; Sandra Weickhardt; Gabriele Röhn; Marco Timmer; Roland Frötschl; Niels Eckstein
Journal:  Cancer Cell Int       Date:  2018-05-04       Impact factor: 5.722

Review 6.  Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article.

Authors:  Georgios V Koukourakis; Vassilios Kouloulias; Georgios Zacharias; Christos Papadimitriou; Panagiotis Pantelakos; George Maravelis; Andreas Fotineas; Ivelina Beli; Demetrios Chaldeopoulos; John Kouvaris
Journal:  Molecules       Date:  2009-04-16       Impact factor: 4.411
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.